T cells expressing Bi-ChTCRs targeting CD19 and CD22 or BCMA and SLAMF7 recognized target cells expressing either one or both target proteins and exhibited superior sensitivity for tumor cells with low antigen levels compared to T cells expressing monospecific and bispecific CARs. This evidence concerns the gene CD22 and neoplasm.